

AMS Approved Projects

Last updated 08/11/2022

AMS ID	Project Name	Project Lead	Keywords
1	SNORE Methods	DR Stephanie Ward	sleep, breathing, cognitive
2	Aspirin for the prevention of cognitive decline in the Elderly: a Neuro-Vascular Imaging Study	PROF Walter Abhayaratna	vascular, retinal, white matter hyperintensities, aspirin, cognition
3	AUS Biobank	PROF John McNeil	biomarker, sample, biobank, cancer, dementia
4	ASPREE Neuro Substudy Proposal	PROF Elsdon Storey	Neurology, White matter, Hyper-intensity
5	ASPREE Longitudinal Study of Older Persons	PROF John McNeil	healthy ageing, social, medical, lifestyle, behaviour
6	Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea	PROF Elsdon Storey	sleep, sleep disordered breathing, cognition, retinal , vascular
7	Aspirin to Inhibit Sepsis	PROF Damon Eisen	infection, ICU, sepsis, mortality
8	ASPREE AMD (Age-related Macular Degeneration)	PROF John McNeil	macular degeneration, macula, aspirin, blindness, AMD
9	ASPREE Cancer Endpoints Study	PROF John McNeil	cancer, specimen, biomarkers, saliva, biobank
10	Cardiovascular Risk Factors in a Healthy Older population	PROF Christopher Reid	cardiovascular, modelling, risk factors, healthy elderly
11	Assessment of knee muscles: effect on knee structure and function Substudy	A/PROF Anita Wluka	Knee, Structure and function, Muscles
12	ASPREE 'big data' solutions for prescription medication analysis	DR Jessica Lockery	AWARD, Medication Use, Polypharmacy, Recruitment and Project Management
13	Defining an epigenetic signature which distinguishes individuals with dementia from those cognitively	DR Joanne Ryan	Dementia, Epigenetics, D Methylation, Signature, Biomarker
14	ASPREE Web Accessible Relational Database (A.W.A.R.D) – Workflows for efficient project management	DR Jessica Lockery	Relational Database, A.W.A.R.D, Data Science
15	Whole Genome Sequencing substudy	A/PROF Robyn Woods	genomics, whole genome, cancer, dementia, cardiovascular
16	Exploring pain and analgesic use in healthy older people	DR Julia Gilmartin	Pain, Analgesic Use, Healthy Elderly, ALSOP

17	Relationship between dynamic resting-state functional connectivity and cognition in ageing	DR Sharna Jamadar	fMRI, Cognition, Resting State, Connectivity, Ageing
18	Effects of Age on Central Auditory Processing	PROF Gary Rance	Central Hearing, Evoked Response, Speech Reception
21	Plasma lipidomic profiling to predict metabolic and cardiovascular disease and the effect of aspirin	A/PROF Peter Meikle	lipidomics, biospecimen, cardiovascular
22	Baseline Cancer History in the ASPREE population	DR Suzanne Orchard	ASPREE, Cancer, Cancer prevalence, Aspirin and cancer
23	Mt Sinai Resilience Project	PROF John McNeil	resilience, genomic, cancer, dementia, cardiovascular
24	ASPREE Healthy Ageing Biobank baseline cohort	DR Emily Parker	ASPREE Healthy Ageing Biobank, Biospecimen, Demographics
25	ASPREE-Fracture Substudy	DR Anna Barker	NA
26	ASPREE Clinic Vehicles – technical manuscript	DR Emily Parker	biobank, vehicle, mobile, sample collection, camera
28	Angiotensin Converting Enzyme Inhibitors, statins and Risk of Mood Disorders	DR Mohammadreza Mohebbi	comorbid depression, high blood pressure dyslipidaemia, diabetes melitus, obesity, low bone mineral density
29	Recent stressful events in later life and their association with cognitive function and mental well-	DR Joanne Ryan	Stress, Cognition, Depression
30	Visit-to-Visit Blood Pressure Variability, Cognitive Function, and Brain Matter Changes in Healthy C	PROF Michael Ernst	cognition, hypertension, blood pressure, variability, brain
33	Baseline Quality of Life for Participants in the ASPREE (Aspirin in Reducing Events in the Elderly)	PROF Nigel Stocks	Quality of life, Ageing, Primary prevention
34	Baseline ASPREE lipid measures and their association with neurocognitive and physical function measu	PROF Elsdon Storey	Elderly, Correlates, Cognition
35	Prescription medication use in the ASPirin in Reducing Events in the Elderly (ASPREE) cohort	DR Jessica Lockery	Elderly pharmacoepidemiology , Polypharmacy, Prescription Drugs
36	ALSOP PHYSICAL ACTIVITY QUESTIONNAIRE VALIDATION	DR Alice Owen	ALSOP, physical activity, validation
37	Glucometabolic health in the elderly	PROF Sophia Zoungas	diabetes, elderly, statin, insulin, complications
38	Resilience to dementia in APOEε4/ε4 Homozygotes	DR Paul Lacaze	Alzheimer's AD, dementia, resilience, APOE
39	The prevalence of depression in elderly population with chronic health problems	DR Mohammadreza Mohebbi	comorbid depression, high blood pressure dyslipidaemia, diabetes melitus, obesity, cancer
40	Associations of Self-Reported Sleep Quality in the Healthy Elderly	DR Stephanie Ward	sleep quality, sleep wake disorders, cognition, disease, polypharmacy

41	Does low-dose aspirin prevent adverse health outcomes attributable to air pollution exposure – a fea	DR Gavin Pereira	Air Pollution, Low Dose Aspirin, Health Outcomes, cardiovascular disease
42	Dietary Patterns and Quality of Life in Older Adults	DR Alice Owen	Diet, Quality of Life, Healthy Ageing
43	Linking pathogenic variants with baseline disease history and self-reported family history in ASPREE	DR Paul Lacaze	pathogenic variants, ASPREE, penetrance , whole genome sequence, Resilience
44	Neuro Baseline	PROF John McNeil	Cerebral microbleeds, Cognitive decline, Dementia, Small vessel ischaemic disease
45	How to measure Social-Economic Position (SEP) in ASPREE	DR Rosanne Freak-Poli	socio-economic position, education, occupation, social class, older adult
46	Associations of Social Support and Social Isolation in Healthy Older Adults	DR Rosanne Freak-Poli	Social Support, Social Connection, Social Isolation, Socio-economic Position, Older Adult
47	Health Related Quality of Life, Socialising, Difficulty and Psychological health in Healthy Older Ad	DR Rosanne Freak-Poli	Health related quality of life, socialising, psychological well-being, depression, older adult
48	Patterns and Associations of Alcohol intake in Older Adults	DR Rosanne Freak-Poli	Alcohol Drinking, Frail Elderly, Aged, 80 and over, Aged
49	ALSOP Methods and Cohort Profile	DR Alice Owen	ALSOPMethods, Longitudinal cohort
50	Use and predictors of proton pump inhibitors in the elderly, general population	DR Suzanne Mahady	Proton pump inhibitors, antacids, safety, epidemiology
51	Upper & Lower gastrointestinal bleeding in the elderly and impact of low dose aspirin.	DR Suzanne Mahady	aspirin, bleeding, risk, probability
52	ASPREE Recruitment Methods Paper	DR Jessica Lockery	Recruitment, General practitioner, Australia
53	The unworried or worried well? Complementary medicine use and anxiety in healthy older adults	DR Alice Owen	lifestyle risk factors, vitamins, anxiety, anxiety
54	Musculoskeletal Health in the ASPREE/ALSOP cohort	PROF Flavia Cicuttini	joint pain, musculoskeletal, lower limb function, multimorbidity, function
55	Patterns and associations of Tobacco Use in Healthy Older Adults	DR Rosanne Freak-Poli	Tobacco Aged, 80 and over, Aged, smoking, Nicotine
56	Does parenthood lead to long-lasting changes in the human brain	DR Sharna Jamadar	maternal brain, motherhood, fatherhood, cortical thickness
57	Aspirin and Frailty in the ASPREE population	A/PROF Robyn Woods	frailty, Fried criteria, grip strength, gait speed, disability
58	ASPREE AF	A/PROF Amy Brodtmann	Atrial Fibrillation, Dementia, Stroke

59	Genomic ageing – relationship between genetic and phenotypic biomarkers of ageing	PROF David Thomas	Whole Genome Sequencing, MGRB, Ageing, Frailty, Biomarkers
60	Urinary incontinence in healthy Australian adults over 70: incidence, prevalence and causal associat	MS Janice Cheng	urinary incontinence , causal associations, incidence, prevalence
61	ASPREE Joint Replacement	PROF Flavia Cicuttini	joint, knee, replacement
62	ASPREE Biobank Clinical Measures	DR Emily Parker	Clinical measures, Routine pathology, Biospecimen analysis
63	Utility of internet and community resources for death detection in ASPREE	MS Anna Tominaga	Clinical trial, Death detection, Data linkage
64	A Pilot Dementia Clinical Quality Registry to Improve Dementia Clinical Care	PROF John McNeil	Dementia, Clinical Quality Registry, Minimum Data Set, Clinical Quality Indicators, Dementia Registry
65	ALSOP Hearing	DR Carlene Britt	ASPREE, Hearing, Ageing, Disability, Tinnitus
67	ASPREE-CHIP sub-study	DR Zoe McQuilten	clonal haematopoiesis, haematological cancer, cardiovascular disease
68	Dental Health in Older Australians	DR Carlene Britt	dental, elderly, edentulism, self report
69	Sex Hormones in Older Women Study-SHOW	PROF Susan Davis	sex steroids, androgen, women, ageing
70	Relationship between Chronic Kidney Disease (CKD) and Measures of Frailty in the Elderly: Baseline D	PROF Rowan Walker	frailty, ckd, disability, creatinine, adverse outcomes
71	Repeat DNA extraction and sequencing of failed Australian buffy coat samples	DR Paul Lacaze	D Sequencing, Genomics
72	PhD The characterisation and role of epigenetics in dementia: Early diagnosis and predicting risk	DR Joanne Ryan	D Methylation, Dementia, Diagnosis
73	Epigenome wide association study (EWAS) validation of DNA methylation signatures of dementia	DR Joanne Ryan	Biomarker, Epigenetics, Dementia, D Methylation, Diagnosis, Epigenetics,
74	Analysis by aspirin status at study entry.	PROF Mark Nelson	Aspirin, Cessation, Benefit, Harm
75	Prevalence of chronic kidney disease in the elderly using the ASPREE cohort	A/PROF Kevan Polkinghorne	Elderly, eGFR, Chronic Kidney Disease, Albuminuria, Prevalence
76	Kidney disease progression and effect of long term exposure to aspirin in ASPREE	PROF Anne Murray	Chronic Kidney Disease, albuminuria, Progression CKD, estimated glomerular filtration rate, safety
77	Genome-wide SNP genotyping of all ASPREE biobank samples	DR Paul Lacaze	Genomics, SNPs, Biobank
78	HVLT-R Normative Data	PROF Elsdon Storey	dementia, cognition, HVLT-R, normative data
79	Kidney disease and outcomes in ASPREE: assessment of an elderly specific GFR equation	PROF Anne Murray	Chronic Kidney Disease, eGFR, Kidney Function

80	Efficacy and safety of aspirin in participants with CKD	A/PROF Kevan Polkinghorne	Chronic Kidney Disease, Safety, cardiovascular disease
82	Genetic Analysis - Cognition, dementia & Alzheimer's disease	DR Paul Lacaze	Cognition, Genomics, Alzheimer's, APOE
83	Genetic Analysis - Cancer	DR Paul Lacaze	genomics, cancer, penetrance
84	Genetic Analysis - Cardiac	DR Paul Lacaze	genomics, cardiac, penetrance
85	Genetic Analysis- Predictive Modelling Chronic Diseases	DR Paul Lacaze	genomics, common disease, risk modelling, polygenic
86	Genetic Analysis - Pharmacogenomics & Polypharmacy	DR Paul Lacaze	pharmacogenomics, genomics, polypharmacy
87	Genetic Analysis - Resilience	DR Paul Lacaze	genomics, resilience, penetrance
88	ASPREE Loss of Y and X chromosome	DR Paul Lacaze	Y chromosome , x chromosome, somatic, Clonal hematopoiesis CHIP, genomics
89	HLA haplotypes in relation to disease risk and other phenotypes in ASPREE	DR Paul Lacaze	HLA, Genomics, MHC
90	Analysis of the CFTR gene in ASPREE	DR Paul Lacaze	cystic fibrosis, carrier status, heterozygote, genomics
91	Analysis of the PRF1 gene in ASPREE	DR Paul Lacaze	PRF1, Cancer, Resilience, Genomics
92	Genetic analysis of depression in ASPREE	DR Paul Lacaze	Depression, Genetics, Polygenic
94	Understanding causes and consequences of anaemia in the elderly – the ASPREE-Anaemia substudy	DR Zoe McQuilten	Anaemia, iron, myelodysplasia, functional outcomes
97	ANTISEPSIS_OutcomePaper	PROF Damon Eisen	sepsis, death, hospitalisation, prevention
98	Body weight and ASPREE Outcomes	A/PROF Robyn Woods	primary endpoints, secondary endpoints, bodyweight, aspirin dose
100	Mitochondrial disease in Aspre	DR Paul Lacaze	Mitochondrial disease, Mitochondria, Genomics
101	Effect of statins in the healthy elderly: A post-hoc analysis of the ASPREE trial	PROF Mark Nelson	statin, mortality, cardiovascular disease, elderly
102	ASPREE-D SUBSTUDY	PROF Michael Berk	Depression, Elderly, Biomarkers
103	ASPREE-D OutcomePaper	PROF Michael Berk	ASPREE-D Depression bio-markers, antidepressants, aspirin, inflammation, immunology
106	Association between cognitive function and mood in non-demented older individuals	DR Joanne Ryan	cognition, cognitive performance, depression, mood
107	Social isolation and disability free survival in older Australians	DR Rosanne Freak-Poli	Social isolation, Social support, Social connection, Social interaction, Loneliness

108	Statins and Cognitive Function	DR Joanne Ryan	statins, dementia, cognition
109	ASPREE-Dementia Outcome Paper	PROF Elsdon Storey	Dementia, Aspirin, Alzheimer's disease
110	Mild Cognitive Impairment ASPREE Outcome Paper	PROF Elsdon Storey	Mild cognitive impairment, Cognitive decline, Aspirin
111	ASPREE-Hearing: substudy proposal 2014	PROF Elsdon Storey	hearing, elderly, presbycusis
112	ASPREE-Hearing PhD project	DR Carlene Britt	Hearing, verbal fluency, elderly
113	ASPREE-HEARING Baseline	DR Carlene Britt	hearing loss, epidemiology, older adults, risk
114	ASPREE HEARING Self report and audiometry	DR Carlene Britt	age related hearing loss, prevalence, presbycusis
115	ALSOP Social Determinants of Mental Health	PROF Jane Fisher	mental health, trajectories, social determinants
116	Implications of the ASPREE trial for aspirin use in healthy elderly; comparing Australia and US	PROF Rory Wolfe	country differences, aspirin effect, population subgroups
117	Impact of aspirin on ConMed use and outcomes	DR Jessica Lockery	ConMeds, Cancer mortality, Aspirin side effects
118	ANTISEPSIS and ASPREE Mortality	PROF Damon Eisen	aspirin, prevention, sepsis, death, hospitalisation
119	BP variability and CVD outcomes	PROF Michael Ernst	blood pressure variability, cardiovascular events, hypertension
120	Blood Pressure Variability and Cognitive Function	PROF Michael Ernst	blood pressure variability , dementia, cognition
121	Cardiovascular outcomes in the SHOW study	PROF Susan Davis	sex hormones, cardiovascular, all cause mortality
122	Cognition and sex hormones in SHOW	PROF Susan Davis	dementia, sex steroids, frailty
123	Cancer outcomes and sex steroids in SHOW	PROF Susan Davis	cancer, sex steroids, women
124	Fractures and sex steroids in SHOW	PROF Susan Davis	fractures, hormones, women
125	SHOW baseline analysis	PROF Susan Davis	SHOW, sex steroids, baseline analysis
126	Baseline CVD risk and cardiovascular outcomes in the elderly – Findings from the ASPREE Trial	PROF Christopher Reid	CVD outcomes, CVD, risk, Risk equations, Modelling
128	ASPREE Normative Data COWAT SDMT	DR Joanne Ryan	SDMT, COWAT, normative data, Cognition
130	The genetics of social isolation	DR Rosanne Freak-Poli	Social isolation, Loneliness, Genetics, Social Support, Older Adult
131	Physical exercise and cognition in ASPREE	DR Suzanne Orchard	Physical activity, Cognition, Primary prevention

132	Cancer and Depression	DR Suzanne Orchard	cancer, depression, risk factor
133	The effect of physical activity on CVD outcomes	DR Danijela Gasevic	physical activity, mortality, CVD, older adults
135	Aspirin, statins, fish oil use, and CV events in ASPREE	DR Alice Owen	fish oil, statins, aspirin, cardiovascular outcomes
136	Impact of opiate medication on CV outcomes	PROF David Kaye	opiates, heart failure, cardiac events
137	PEAR1 Gene and aspirin response in ASPREE	DR Paul Lacaze	genomics, aspirin, PEAR1
139	Obesity, hypertension and anti-hypertensive medications in CV outcome	PROF David Kaye	obesity, antihypertensive, outcomes
141	Association between multiple Cardiovascular Risk factors and Depression-ASPREE-ALSOP basel	PROF Michael Berk	depression, stress, cardiovascular risk factors
142	Depression/antidepressant use and cognitive decline/dementia incidence	DR Joanne Ryan	dementia, depression, antidepressants
143	Associations between risk factors, protective factors and cancer	DR Suzanne Orchard	Cancer, Cancer risk factors, Lifestyle
144	Correlation of whole genome measures with ASPREE endpoints and functional ageing phenotypes	DR Paul Lacaze	genomics, somatic, WGS
145	Effect of aspirin on stroke subtypes	PROF Geoffrey Cloud	ischaemic stroke subtypes, aspirin, prevention
147	Colonial Foundation Centre for Healthy Ageing	A/PROF Andrew Webb	Mass spectrometry, Dementia, Biomarkers, Pathology, Diagnostics
149	Inflammatory Biomarker Pilot ASPREE longitudinal data	DR Emily Parker	Biomarkers, Inflammation, Aspirin, Ageing
151	Aspirin and dementia incidence with single domain executive dysfunction at baseline	A/PROF Shahram Oveisgharan	Executive dysfunction, Cognitive decline, Dementia, Stroke
152	Genetic analysis of the platelet thrombin receptor PAR4 gene & cardiovascular disease	A/PROF Justin Hamilton	PAR4, Thrombin, Genomics
153	Per-protocol analysis of primary and secondary outcomes adhering to ASPREE statistical analysis plan	PROF Rory Wolfe	per-protocol, primary endpoint, secondary endpoints
154	Aspirin effect on eGFR, albuminuria, CKD stage, frailty	PROF Rowan Walker	CKD, change in CKD, frailtyalbuminuria,
155	Analysis of kidney-disease genes in ASPREE	DR Paul Lacaze	genomics, genetics, kidney disease, renal, penetrance
158	Investigating functional neuroimaging biomarkers and sex differences in ASPREE-NEURO and -HEARING	DR Sharna Jamadar	functional brain activity, hearing loss, cognitive decline
160	AMD Baseline Paper	DR Liubov Robman	baseline, elderly, non-mydratic colour photography, age0related macular degeneration, aspirin,
161	AMD Outcome Paper	DR Liubov Robman	AMD, macular degenerationincidence, progression, aspirin,
162	Association between multiple Cardiovascular Risk factors and Depression-Longitudinal	PROF Michael Berk	depression, stress, cardiovascular risk factors

163	Natural Language Processing model ICD10 code for cause of death	DR Jason Rigby	natural language processing, cause of death, death certificate data, unstructured health data
164	Methods to examine evidence of time-dependent effects of aspirin on bleeding and MACE	PROF Rory Wolfe	time-to-event analysis, non-proportional hazards, flexible parametric models
166	Predictors of Vascular events in the elderly using multivariate modelling	DR Johannes Neumann	cardiovascular, modelling, risk prediction
167	Body habitus healthy lifestyle and cardiovascular disease in the elderly	DR Prue Carr	cardiovascular, obesity, BMI, MACE, Survival
170	Temporal hierarchy of non-fatal events, disability and mortality	DR Johannes Neumann	cardiovascular, disability, temporal trend
171	ASPREE ConMed collection and classification methods	DR Jessica Lockery	Concomitant medications, Neural Network, AWARD, Health technology optimisation
172	AMD and Sleep Apnea	PROF Robyn Guymer	age-related macular degeneration, sleep apnea, association
173	ASPREE-D Methods: Aspirin for the prevention of depression in the elderly	PROF Michael Berk	Depression, Elderly, Methods
174	Psychometric Properties of the CESD-10 Scale	PROF Michael Berk	Depression, Elderly, CESD-10
175	ASPREE Gut Microbiome Substudy	PROF Andy Chan	aging, healthspan, cognitive decline, frailty, gut microbiome,
177	ASPREE Substudy Retinal and Amyloid Imaging	A/PROF Peter van Wijngaarden	Retinal Imaging, PET/MRI, Dementia
178	ASPREE Late Life Depression and Telomere length	PROF Michael Berk	late-life depression, telomere , mitochondrial D depression, inflammation
179	Late Life Depression and Hippocampal size and other brain morphology	PROF Michael Berk	late-life depression, vascular depression, hippocampus, MRI, brain imaging
180	Late Life Depression and Physical Activity	PROF Michael Berk	late-life depression, depression, physical activity, mood disorder, lifestyle
181	Late Life depression and dispositional optimism	PROF Michael Berk	late-life depression, dispositional optimism, depression, mood disorder, cognitive style
183	PhD Factors associated with depression in older adults: data analyses of the ASPREE cohort	PROF Michael Berk	late-life depression, depression, mood disorder, geriatric depression, old-age depression
184	Effects of Blood Pressure Variability on Cognition and Brain Structure in Healthy Elderly Adults	DR Sharna Jamadar	grey matter, white matter, blood pressure, cognition

185	PhD ASPREE Closest Contacts and Quality of End of Life Care	DR Zoe Keon-Cohen	End of life, Quality of death, Questionnaire
186	ASPREE Closest Contacts and Quality of End of Life Care	DR Zoe Keon-Cohen	End of life, quality of death, palliative care, questionnaire
187	CKD Cognitive Decline and Aspirin	PROF Anne Murray	chronic kidney disease, cognitive decline, MCI, dementia, aspirin interaction
189	Optimism and health outcomes in the healthy elderly	MS Heather Craig	health outcomes, mortality, CVD, optimism
190	Blood pressure variability and renal outcomes	PROF Michael Ernst	blood pressure variability, renal, chronic kidney disease
191	Methods to examine evidence of time-dependent effects of aspirin on bleeding and MACE	PROF Rory Wolfe	time-to-event analysis, time-dependent effects, non proportional hazards
193	PhD Frailty and Cardiovascular Disease	DR Ekram Saifuddin	FrailtyCVD outcomesASPREE, Fried phenotype, Frailty deficit accumulation index
194	ASPREE Frailty and Cardiovascular Outcomes	DR Ekram Saifuddin	Frailty, Disability, CVD outcomes, FDAI
196	PhD- Quality of Life in the Elderly and Survival	MR Aung Phy	Elderly, Survival, Health-related Quality of Life
197	QoL and all-cause mortality among the healthy elderly	MR Aung Phy	Health-related Quality of Life , all-cause mortality, the Healthy Elderly
200	Description of self-reported weight over the course of a lifetime	MS Tagrid Alharbi	weight change; Weight trajectory; weight loss, Aged; Geriatric, Cardiovascular disease
201	Demographic and socioeconomic correlates of weight change in older adults	MS Tagrid Alharbi	Cardiovascular disease, Older Adult; Frail Elderly; Aged, 80 and overweight change; Weight trajectory; weight loss;
202	Clinically significant bleeding sites in the elderly and impact of low dose aspirin.	DR Karen Margolis	haemorrhageepidemiology, elderly
203	ASPREE blood cancers and aspirin	DR Zoe McQuilten	blood cancer, aspirin, incidence, blood cancer, aspirin, incidence, blood cancer, aspirin, incidence
204	Pilot Next of Kin Perceptions and Quality of End of Life Care	DR Zoe Keon-Cohen	End of Life, elderly, pilot, questionnaire
205	Development of Participation Life Years in ASPREE/ALSOP	DR Alice Owen	Participation, Modelling, Socioeconomics, Activity
207	Preclinical epigenetic biomarkers of dementia	DR Joanne Ryan	Epigenetics, biomarkers, dementia, dna methylation, EWAS

208	The epigenetic clock and dementia	DR Joanne Ryan	D methylation age, epigenetic clock, dementia
209	Anaemia: Incidence, Risk Factors and the Effect of Aspirin in the Healthy Older Population	DR Zoe McQuilten	anaemia, haemoglobin, aspirin, bleeding, blood cancer
210	PhD eHealth literacy barriers and enablers in older adults	MS Tara Johnson	eHealth Literacy, Health Technology, Older Adults, Barriers and Enablers, Medical Conditions
211	A Longitudinal study of factors associated with older adults' daily computer use	MS Tara Johnson	Computer Use, Electronic Health, Health and Wellbeing, Digital Technology, Barriers
214	Association between lower back pain and indices of body mass	DR Julia Gilmartin	back pain, weight, body mass index
216	Endpoint Data for AUS Biobank	A/PROF Robyn Woods	Biospecimen, Endpoint, Death, Disability, Dementia
217	Anticholinergic Medication Use and Outcomes	DR Jessica Lockery	Anticholinergics, Adverse Drug Reactions, Modifiable dementia risk factors, Dementia, Stroke
218	ALSOP Pain Impact Index	DR Julia Gilmartin	pain, older person, index
220	Low-dose aspirin for the prevention of fractures in healthy older people: ASPREE-FRACTURE	DR Anna Barker	Falls, Fractures, Aspirin, Elderly, Effectiveness
221	Functional Connectivity and Correlations with Behaviour	DR Sharna Jamadar	Functional connectivity, functional connectome-haemoglobin, haematocrit, fMRI
222	VACAR: Cardiac arrest and ASPREE	DR Vazhma Qaderi	hospital, cardiovascular, arrest, ambulance
223	Impact of cancer survivorship on the development of chronic conditions	MR Jaidyn Muhandirange	cancersurvivor, chronic disease
225	Defining cognitive trajectories in ASPREE	DR Joanne Ryan	cognition, cognitive trajectories, dementia, risk factors
226	Parenthood and functional connectivity in the elderly	DR Sharna Jamadar	fMRI, Resting State, Connectivity, Parenthood, Ageing
227	Comparing mortality among ASPREE participants with dementia and MCI with healthy controls	PROF Jane Banaszak-Holl	dementia, mild cognitive impairment, mortality, survival analysis
229	ASPREE AMD Genomics	DR Paul Lacaze	AMD, Genomics, Baseline
233	Late Life Depression and RVI (2)	PROF Michael Berk	late-life depression, depression, retinal scans, retinal vascular imaging , vascular depression
234	Late Life Depression and Epigenetic Ageing	PROF Michael Berk	late-life depression, epigenetic, methylation, ageing

235	Late Life Depression and Mortality	PROF Michael Berk	late-life depression, mortality, ageing, depression, mood disorders
236	Investigating Brain Ageing	MS Jo Wrigglesworth	Brain age, Ageing, Biomarker, Dementia, Cognition
237	QoL and cognitive decline / dementia in ASPREE	MR Aung Phyo	Health-related Quality of Life, Cognitive Decline, Dementia
238	Association of Statin Therapy with Disability-Free Survival and Cardiovascular Outcomes among Healthy Adults 70 Years or Older	PROF Mark Nelson	statins, elderly, disability-free survival, cardiovascular disease
239	Dementia Diagnosis in ASPREE	PROF Jane Banaszak-Holl	dementiaclinical diagnosis, clinical quality registry, quality indicator
240	Analgesic use in low back pain	DR Julia Gilmartin	pain, low back, analgesic
241	Dementia Registry Methods	PROF Jane Banaszak-Holl	dementia, diagnosis, challenges
242	Cognition and Proteomics/Metabolomics in ASPREE	A/PROF Andrew Webb	cognition, proteomic, lipidomic, dementia
244	Cancer Treatment in ASPREE	PROF Andy Chan	cancer survivorship, cancer treatment, cancer related cognitive decline, cancer related physical decline
245	Joint replacement hospitalisations in ASPREE	PROF Flavia Cicuttini	joint replacement, osteoarthritis, hip, knee
246	Diabetes incidence in ASPREE	DR Alice Owen	diabetes, glycaemia, glucose, aspirin, epidemiology
247	Diabetes and health outcomes in ASPREE	DR Alice Owen	diabetes, vascular outcomes, pre-diabetes risk, model, prediction
248	Application of established risk prediction models in elderly individuals	DR Johannes Neumann	
249	Association of cardiac and inflammatory biomarkers with future events	DR Johannes Neumann	biomarker, prediction, cardiac, inflammatory
250	Improvement of risk prediction based on biomarkers	DR Johannes Neumann	biomarker, risk model, cardiac, inflammatory
251	Trajectory of depressive symptoms in the ASPREE cohort	PROF Michael Berk	late-life depression, trajectory of depression, mood disorders
252	Updated collaborative meta-analysis of individual participant data from all large-scale randomized trials of aspirin vs control for the primary prevention of cardiovascular disease	PROF Colin Baigent	Aspirin, Individual participant data meta-analysis, Major vascular events, Bleeding, Disutility analyses
253	ASPREE-Neuro Brain age project	MS Jo Wrigglesworth	Brain age, Biological age, Biomarker, Ageing, Machine learning
255	Dual Decline in Cognition and Gait Speed	MRS Taya Collyer	dementia, gait, cognition
256	The prognostic value of biomarkers in healthy elderly patients undergoing surgery	DR Johannes Neumann	surgery, risk, biomarkers

257	ASPREE Verbal fluency clusters	MR Caleb Drewitt	Clusters, Verbal Fluency, 3MSSemantic Memory, Hearing Threshold,
258	PRICEY: PProton pump Inhibitors and Cognition in the Elderly	DR Bharati Devi Kochar	Cognition, Pharmacoepidemiology, Proton Pump Inhibitors
259	ASPREE-VACAR Pilot Data Linkage	DR Vazhma Qaderi	cardiac arrest, ambulance, cardiovascular
260	Risk of bleeding with chronic kidney disease and aspirin in older people: data from a trial of 19,114 persons	DR Suzanne Mahady	bleeding, CKD, aspirin, bleeding, aspirin
265	Economic, life experience and social correlates of Physical HRQoL (PCS) trajectories	MR Aung Phyo	Physical Component of HRQoL, Longitudinal Trajectories, Life Events , Economic Factors, Social Factors
268	Pain on most days and analgesic use, over time	DR Julia Gilmartin	pain, analgesic, medication
272	The effects of aspirin on melanoma incidence and mortality in the elderly	PROF Rory Wolfe	melanoma, aspirin, chemoprevention
273	Body habitus and disability and frailty risk in ASPREE participants	DR Joanne Ryan	body habitus, waist circumference, BMI, disease risk
274	Identifying rare protective genetic variants in ASPREE participants and their family members for highly penetrant familial cancer syndromes	DR Paul Lacaze	genomics, cancer, return of results
275	Cancer and NSAIDS in ASPREE	DR Farzana Zaman	non-steroidal anti-inflammatory drugs, cancer, aspirin, cancer incidence
278	Physical activity and obesity and risk of fall-related hospital presentations and fractures	DR Julia Gilmartin	falls, fractures, body mass index, weight, pain
279	Body habitus and cognition and dementia risk in ASPREE participants	DR Joanne Ryan	dementia, cognition, BMI, Waist Circumference
280	Obesity and change in oral health	DR Danijela Gasevic	obesity, oral health, BMI, waist circumference, oral health related quality of life
281	Health-related Quality of Life and cardiovascular diseases (CVD) incidence and mortality	MR Aung Phyo	Health-related Quality of Life , cardiovascular disease incidence , cardiovascular disease mortality
282	Association of statin use with onset and worsening of diabetes in the elderly	MS Zhen Zhou	statin, diabetes, aged
283	ASPREE Pneumonia	PROF Damon Eisen	pneumonia, stroke, acute coronary syndrome, cohort, self-controlled
284	Oral health and ASPREE outcomes	DR Danijela Gasevic	oral health, dementia, all-cause mortality, disability-free survival, cardiovascular disease

285	Known risk factors for dementia and cognitive decline	DR Joanne Ryan	dementia, cognitive decline, Alzheimer's Disease, Risk Factors
286	Back and lower limb pain and self - reported falls in ALSOP	DR Julia Gilmartin	falls, pain, mobility
287	Hypertension and Falls	DR Monira Hussain	Hypertension, Cardiovascular disease, Falls , Fracture, Medication
288	Effect of Metformin on ASPREE outcomes	DR Sara Espinoza	metformin, diabetes, frailty, disability free survival, cancer
291	Sleep quality as a predictor of psychiatric and physical functioning in the healthy elderly	MS Amie Hayley	Sleep, Psychiatric , Older adult
292	Preventive drugs in older age – use, costs and benefits in the healthy, older Australian population	A/PROF Emily Callander	health economics, Preventive drugs, Value based healthcare, Pharmaceutical policy, inequality
294	An epidemiology and health economics assessment of health service costs	A/PROF Emily Callander	Health economics, Disability, Policy, Aged care, Costs
295	Antibiotics, aspirin and cancer	PROF Finlay Macrae	cancer, aspirin, antibiotics, chemoprevention, , microflora, drug interaction
296	CVD and cognitive decline	MS Swarna Vishwanath	Cognitive decline, Dementia, Cardiovascular disease
297	Polypharmacy, supplement use, and indicators of medication-taking behavior in ASPREE	DR Alice Owen	polypharmacy, medications, supplements
298	The association between pain, depression and cognition, over time	DR Julia Gilmartin	pain, analgesic, antidepressant, depression
299	The impact of pain on sleep, over time	DR Julia Gilmartin	pain, analgesic, sleep
300	The impact of pain on quality of life, over time	DR Julia Gilmartin	pain, analgesic, quality of life
301	Returning genetic results to ASPREE participants (BRCA1/2, Long-QT syndrome)	DR Paul Lacaze	genomics, genetics, BRCA, Long QT
302	ASPREE Joint replacement and Osteoarthritis genomics	DR Paul Lacaze	osteoarthritis, polygenic risk score, joint replacement, hip, knee
303	ASPREE NDLD linkage	PROF Rory Wolfe	Dementia, Data linkage, Data validation, Prevalence
304	Cerebral microbleeds and relationship to stroke outcomes	DR Prue Carr	blood pressure, hypertension, cerebral microbleeds, stroke
305	Relationships Between Blood Pressure Trajectories, Functional Status, and ASPREE Principal Outcomes	PROF Michael Ernst	blood pressure, trajectory, functional status
306	A study of the relationships between retinal pathology and cerebral microbleeds	DR Prue Carr	cerebral microbleeds, retinal haemorrhages, blood pressure, stroke
307	ASPREE PCS 'Coding for dementia' data linkage study	PROF Velandai Srikanth	Dementia, Data Linkage, EMR, Coding,

308	Trajectories of functional decline following a community diagnosis of dementia or MCI	DR Xiaoping Lin	dementia, activities of daily living, cognitive impairment, functional decline
311	Retinal vascular changes and ASPREE	DR Liubov Robman	retinal digital imaging, grading, retinal vascular caliber
313	Variability in Renal Function and Association with Disability-Free Survival	PROF Michael Ernst	disability free survival, kidney function variability, chronic kidney disease
316	Frailty and ASPREE outcomes	DR Ekram Saifuddin	Frailty, ASPREE outcomes, Fried phenotype, Frailty deficit accumulation index
317	Body habitus lifestyle and cancer	DR Prue Carr	weight, body size, cancer, mortality, healthy lifestyle
319	ASPREE-PCOR Registry Linkage	DR Prue Carr	prostate cancer, registry, data linkage, survival, outcomes
320	The risk of low to moderate alcohol consumption on incident cardiovascular disease	DR Johannes Neumann	alcohol, cvd, cardiovascular disease
321	Meta-analysis of in-trial participant data from recent randomized trials of aspirin vs control	DR Prue Carr	cancer, aspirin, meta-analysis, cancer death, primary prevention
322	Lipoprotein (a) and CVD in ASPREE	DR Vazhma Qaderi	lp(a), cvd, aspirin, genomics, lipid, cvd
323	Brain age and cognition, sociodemographic, health and lifestyle factors	MS Jo Wrigglesworth	Brain age, Ageing, Biomarker, Cognitive decline, Cognitive function
324	Cause specific proportional hazards models with interval censored competing risks - application to ASPREE endpoints	PROF Rory Wolfe	statistical methods, cause-specific hazards, methodology, interval censoring
325	Pharmacogenomic SNPs that impact the effect of aspirin on colorectal cancer outcomes in ASPREE, by CRC location	DR Jessica Lockery	Aspirin, Colorectal cancer, Pharmacogenomics
326	Physical activity and ASPREE outcomes	DR Danijela Gasevic	physical activity, CVD, mortality, disability-free survival, dementia
327	Skipping meals and health outcomes	DR Alice Owen	meal skipping, mortality, dietary patterns
329	Cognitive reserve	DR Joanne Ryan	Cognitive reserve, Occupation, Cognitive stimulating activities, Dementia
330	Alcohol and ASPREE outcomes	DR Johannes Neumann	alcoholmortality, CVD
331	Predictors of high maintenance and decline in cognitive function	MR Zimu Wu	Cognitive function, Trajectories, Modifiable factors

332	Aspirin as chemoprevention for keratinocyte carcinoma incidence and mortality in the elderly	DR Emma Hiscutt	keratinocyte carcinomas, chemoprevention, aspirin,, non melanoma skin cancers, basal cell carcinoma, cutaneous squamous cell carcinoma
333	Social connection, physical capacity and well-being among older adults and caregivers	DR Rosanne Freak-Poli	social connection, care giving, physical capacity, well-being
335	Depression and Cognitive Decline	MR Malcolm Forbes	Depression, Cognition, Cognitive decline
336	Impact of cancer/cancer treatment on cardiovascular outcomes	MR Jaidyn Muhandiramge	cancer, cardiovascular disease, ageing, cancer treatment
337	Impact of cancer/cancer treatment on functional decline	MR Jaidyn Muhandiramge	cancer, physical disability, cancer treatment, functional decline, ageing
339	Use of transport and ASPREE outcomes in older adults	DR Danijela Gasevic	transport use, walking, cycling, ASPREE outcomes, frailty
340	Sedentary behaviour and ASPREE outcomes in older adults	DR Danijela Gasevic	sedentary behaviour, ASPREE outcomes, older adults
341	Plasma lipid concentrations and disability-free survival in the healthy elderly	MS Zhen Zhou	lipids, healthy ageing, disability-free survival
342	Blood Pressure Variability and Brain Structure in Healthy Elderly Adults	DR Sharna Jamadar	grey matter, white matter, blood pressure, cognition
343	Mental health and emergency health service use among older people in Australia	PROF Jane Fisher	Mental health, emergency health service, hospitalisations
344	Fish oil consumption and atrial fibrillation in ASPREE	PROF Michael Ernst	atrial fibrillation, fish oil, supplements, CAM, ALSOP, Milestone visit
345	Physical HRQoL trajectory and cardiovascular diseases (CVD) incidence and all-cause mortality	MR Aung Phy	Cardiovascular disease , All-cause mortality, Trajectory, Physical health-related quality of life
346	Polypharmacy and Frailty	DR Ekram Saifuddin	Frailty , Polypharmacy , Fried phenotype , Mortality, Pre-frailty
347	Hormonal and lifestyle factors associated with a biomarker of brain ageing	MS Jo Wrigglesworth	Brain age, Ageing, Lifestyle, Environmental, Sex hormones
350	Dietary nut intake and health outcomes	DR Alice Owen	nuts, mortality, cardiovascular risk
351	Dietary egg intake and health outcomes	DR Alice Owen	egg, diet, cardiometabolic disease, healthy ageing
352	Aspirin use for prevention of cardiovascular disease – extended follow-up of the ASPREE trial	DR Johannes Neumann	cardiovascular, outcome, aspre
353	ASPREE Sensory/Motor loss and Cognition	A/PROF Michele Callisaya	sensory, motor, dementia

354	Stressful events in later-life and their longitudinal associations with cognitive decline, dementia, and mortality	MS Dinuli Nilaweera	Stress, Cognition, Dementia
356	Impact of sensory and cognitive impairment on the risk of falls and fractures	DR Monira Hussain	sensory impairment, Cognitive impairment, Falls and fracture
359	Death adjudications	PROF Mark Nelson	Death, Adjudication, Certification
360	The effects of aspirin on melanoma incidence and mortality in the elderly - longitudinal analysis	PROF Rory Wolfe	melanoma, chemoprevention, aspirin
362	Blood Pressure Variability and Frailty	PROF Michael Ernst	blood pressure, frailty, blood pressure variability
363	Occupational exposures, psychosocial working conditions and trajectories of disability	DR Sheikh Alif	Occupation, dementia, disability , Occupational exposure, JEM
364	Terminal decline in physical and cognitive function before death.	DR Joanne Ryan	mortality, functional decline, frailty, cognition
365	Associations of depression, quality of life and other psychosocial factors with colorectal cancer	DR Keming Yang	depressionmental health, quality of life, colorectal cancer, psychosocial factors,
366	Epigenome-wide analysis of ASPREE-Neuro participants	DR Joanne Ryan	epigenetics, cognition, MRI, brain age, biological age
367	Occupational exposure, sedentary and nightshift work and risk of cancer	DR Sheikh Alif	Occupational exposures, Cancer, Job Exposure Matrix
369	Lipidomics & genomics	A/PROF Peter Meikle	cvd, lipids, lipidomics, genomics, alzheimers
370	Health impacts of environmental exposure	DR Sheikh Alif	Air pollution , Environment, Mortality , Dementia , Residential greenness
372	Brain Correlates of Sleep Disruptions in Older Adults	DR Bernadette Fitzgibbon	sleep, cognition, dementia, brain, Neuroimaging
373	Cerebral Microbleeds, White Matter Hyperintensities and Cognition	DR Bernadette Fitzgibbon	Cognition, Dementia, Brain, Cerebral Microbleeds, White Matter Hyperintensities
374	Aspirin cessation and short-term impacts	PROF Rory Wolfe	aspirin, bleeding, cvd
375	Handgrip strength, gait speed and risk of falls and fractures	MISS Thao Pham	Handgrip strength, Gait speed, Falls and fractures
377	Vision satisfaction in the elderly	PROF Robyn Guymer	Eyesight, ALSOP, satisfaction
378	Occupational history and hypertension	DR Kathlyn Ronaldson	Occupational history, hypertension, blood pressure control
379	The impact of stressful events on trajectories of depression	DR Bernadette Fitzgibbon	Stress, Depression, Trajectories, Biomarkers, Brain
380	Handgrip strength trajectory and ASPREE health outcomes	MISS Thao Pham	handgrip strength , ASPREE health outcomes, ageing

383	Association between knee muscle properties and health outcomes	DR Yuanyuan Wang	muscle cross-sectional area, muscle fat infiltration , frailty, falls and fracture , physical activity
384	Grip strength trajectories and their associations with ASPREE adverse events	DR Monira Hussain	Handgrip Trajectory, Adverse events, Disability free survival
385	Body weight change and their associations with ASPREE adverse events	DR Monira Hussain	Mortality, Disability, MACE, Weight change
386	Genomic Consortia	DR Paul Lacaze	consortia, genomic, ageing
387	Change in physical activity and ASPREE outcomes	DR Danijela Gasevic	physical activity change, mortality, disability-free survival, cardiovascular disease, dementia
388	Socioeconomic status and ASPREE outcomes	DR Danijela Gasevic	socio-economic status, cardiovascular disease, mortality, dementia, disability-free survival
389	Relationship between medication use and depressive symptoms in older adults	MR Bruno Agustini	depression, medication, drug repurposing
390	Protein intake and healthy ageing	DR Alice Owen	protein , diet, ageing
391	Pain trajectories in older adults	DR Bernadette Fitzgibbon	Pain, Cognition, Depression, Stress, MRI
392	Uptake of low dose aspirin for primary prevention post ASPREE	DR Kathlyn Ronaldson	Low dose aspirin, primary prevention, occupational history, health literacy, education
393	Breast Cancer Association Consortium	DR Paul Lacaze	breast, cancer, consortia, genomic
395	Lifestyle modifies the association between AD genetic risk, brain health and cognitive trajectories	DR Catherine Robb	Lifestyle, Genomics, Dementia, Cognition, Brain health
397	Associations of sleep duration with cardiovascular disease, cancer and mortality	DR Prue Carr	sleep duration, cardiovascular disease, mortality, prevention
398	Polygenic risk score for hearing loss and effect of health, environment and lifestyle	DR Catherine Robb	Hearing, Polygenic risk score, Ageing, Lifestyle, Occupation
399	Persistent pain in the elderly: impact on lifestyle and quality of life	MS Cammie Tran	pain, quality of life, lifestyle
403	Impact of aspirin on the incidence and outcomes of atrial fibrillation in the elderly	DR Jocasta Ball	atrial fibrillation, aspirin, incidence, outcomes
404	Sugar sweetened drinks and disability free survival	DR Alice Owen	sugar-sweetened beverages, SSB, mortality, nutrition
405	The influence of Aquaporin-4 on the relationship between poor sleep and preclinical dementia	DR Marina Cavuoto	sleep, cognition, genes
406	Blood pressure control and the trajectory of chronic diseases and death among older people with hyper	DR Yongping Bai	Blood pressure control Dysfunction, Death, Disease trajectory
408	NIA pilot project	MS Fatima Irfan	NIA, BRICS, pilot study
410	Validation of the SCORE2-OP in the ASPREE participants	DR Thao Le	validation, score, risk, model

413	ASPREE Diet & Cancer	MISS Satheekaa Palany	Vegetarian Diet, Cancer, Diet, Prevention, GI cancer
414	Retinal Vascular Calibre and Cognition	DR Catherine Robb	cognitiongenetics, retinal vascular calibre, lifestyle
415	Ferritin and Heart Failure	DR Monira Hussain	Ferritin, Heart Failure, Adverse events, inflammation
422	ASPREE Healthy Ageing Biobank Pilot Clinical Measures Analyses	PROF John McNeil	Clinical chemistry, Biomarkers, Analytes, Study outcomes
423	Impact of aspirin on liver cancer and bladder cancer prevention	DR Zhaoyu Li	liver cancer, bladder cancer, cancer prevention
425	Lifestyle and biomedical risk factors for Falls and fracture in ASPREE	DR Monira Hussain	Fracture, bone turnover, Fall
428	Heterogeneity of Treatment Effect and Minority Health	PROF Raj Shah	Minority Health, Heterogeneity of Treatment Effect, Data Science
430	Education and Disability Free Longevity in Older African Americans	PROF Raj Shah	Ageing, Minority, disability-free, longevity, education
433	Provision of SHOW data to Genomics SDrive for GWAS	PROF Susan Davis	genomics, steroids, steroid
436	Optimal Dose of Aspirin for Prevention of Colorectal Adenomas and Cancer	DR Devansh Shah	aspirin, CRC, dose, cancer
438	Corticosteroids in the elderly	A/PROF Anita Wluka	Corticosteroid Frailty, Disability free survival, Cardiovascular disease
443	Central Hearing and ASPREE outcomes	PROF Gary Rance	hearing , brain stem, Auditory, Hearing
444	aspirin & hearing outcomes	MR David Clark	ageing, hearing loss, hearing impairment
446	PSA levels in ASPREE	DR Prue Carr	PSAprostate, older men, prostate cancer
449	ENVISION: aspirin effect and impact of CVD risk factors on RVI, MRI measures and cognitive outcomes	PROF Walter Abhayaratna	mri, rvi, cognition
450	ENVISION+SNORE: relationships among RVI, MRI and cognitive measures	PROF Walter Abhayaratna	mri, rvi, cognition
451	Polypharmacy and high-risk medicines in those who are lonely, socially isolated, lack social support	DR Justin Lee	Polypharmacy, High-risk medications, Social Health
453	Serum uric acid and ASPREE outcomes	DR Md Nazmul Karim	Serum Uric acid, ASPREE outcomes, Gout, Normal range, Mortality
455	ASPREE Chronic pain and falls	DR Joel van Weel	chronic pain, falls, analgesia
456	ASPREE-LIVER	A/PROF William Kemp	FLD, Liver, Fibrosis, Cirrhosis
460	SNORE-ASA outcome papers	DR Stephanie Ward	Sleep Disordered Breathing, Cerebral Small Vessel Disease, Cognition
464	Dietary salt and outcomes in ALSOP	DR Rosanne Freak-Poli	dietary salt, mortality, longevity

466	Social health as a determinant of cognitive change and dementia among healthy older adults	DR Htet Lin Htun	social isolation, social support loneliness, dementia, cognitive change
467	Poor social health as determinants of Cardiovascular disease	MR Achamyelah Birhanu Teshale	Social Isolation, Machine learning, cardiovascular disease, poor social health, geriatrics
470	Allopurinol use and ASPREE outcomes	MS Zhen Zhou	allopurinol, cognition, physical disability, frailty, cardiovascular disease
473	Levels of HDL-C and ASPREE outcomes	DR Monira Hussain	HDL-C, MACE, Mortality, Disability
477	Development of predictive algorithms for dementia and cognitive decline	DR Catherine Robb	Dementia, Cognition, Risk prediction
478	Effect of aspirin on white matter hyperintensity volume and cerebral microbleeds	DR Catherine Robb	Aspirin, Cerebral microbleeds, White matter hyperintensities
481	Risk prediction models for depression in community-dwelling older adults using artificial neural net	DR Mohammadreza Mohebbi	Late-life depression , Artificial Neural Network , Risk prediction model, artificial intelligence, lifestyle factors
482	Levels of thyroid stimulating hormone and disability free survival, major cardiovascular events, fra	MS Cammie Tran	TSH, hyperthyroidism CVD, fractures, cognitive decline,